Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Ayman.

Published byElla Manninen Modified over 5 years ago

Similar presentations

Presentation on theme: "Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Ayman."— Presentation transcript:

1 Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Ayman Saad, Anuj Mahindra, Mei-Jie Zhang, Xiaobo Zhong, Luciano J. Costa, Angela Dispenzieri, William R. Drobyski, Cesar O. Freytes, Robert Peter Gale, Cristina J. Gasparetto, Leona A. Holmberg, Rammurti T. Kamble, Amrita Y. Krishnan, Robert A. Kyle, David Marks, Taiga Nishihori, Marcelo C. Pasquini, Muthalagu Ramanathan, Sagar Lonial, Bipin N. Savani, Wael Saber, Manish Sharma, Mohamed L. Sorror, Baldeep M. Wirk, Parameswaran N. Hari  Biology of Blood and Marrow Transplantation  Volume 20, Issue 3, Pages e1 (March 2014) DOI: /j.bbmt Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Distribution of HCT-CI among the patient cohort (N = 1156).
Biology of Blood and Marrow Transplantation  , e1DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 OS of the 3 risk groups (HCT-CI score = 0, 1-2, and 3). RR indicates relative risk. Biology of Blood and Marrow Transplantation  , e1DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 OS in patients with an HCT-CI score > 0 receiving MEL doses of 140 and 200 mg/m2. Biology of Blood and Marrow Transplantation  , e1DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 OS of patients with different HCT-CI scores with (A) MEL doses of 140 mg/m2 and (B) MEL doses of 200 mg/m2. Biology of Blood and Marrow Transplantation  , e1DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Ayman."

Similar presentations

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S.

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S.
Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.
Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma  Baldeep Wirk, Timothy S. Fenske,

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma  Baldeep Wirk, Timothy S. Fenske,
Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.
A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple.

A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis  Sonali.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis  Sonali.
Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple.

Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple.
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma  Robert F. Cornell, Anita D'Souza, Adetola.

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma  Robert F. Cornell, Anita D'Souza, Adetola.
Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma  Ravi Vij, Shaji Kumar, Mei-Jie Zhang,

Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma  Ravi Vij, Shaji Kumar, Mei-Jie Zhang,
Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk.

Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk.
Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.
Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma  Dan T. Vogl, Tao Wang, Waleska S. Pérez,

Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma  Dan T. Vogl, Tao Wang, Waleska S. Pérez,
Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis  Emma C. Scott, Parameswaran Hari, Manish Sharma,

Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis  Emma C. Scott, Parameswaran Hari, Manish Sharma,
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia  Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia  Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes.
Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.

Similar presentations

Ads by Google